Next-Generation ADPR-Based Therapeutics and Diagnostics

Publication ID: 24-11857561_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation ADPR-Based Therapeutics and Diagnostics,” Published Technical Disclosure No. 24-11857561_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857561_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,561.

Summary of the Inventive Concept

This inventive concept envisions a paradigm shift in ADPR-based treatments, leveraging advanced technologies such as nanoparticle vectors, machine learning algorithms, and wearable devices to revolutionize the prevention, diagnosis, and treatment of adenovirus-related diseases and conditions.

Background and Problem Solved

The original patent disclosed methods for using ADPR to treat various diseases and conditions. However, these methods have limitations, including lack of targeted delivery, limited dosing precision, and inadequate monitoring capabilities. The present inventive concept addresses these limitations by introducing novel systems, methods, and devices that overcome these challenges.

Detailed Description of the Inventive Concept

The inventive concept comprises a suite of innovative solutions, including nanoparticle vectors for targeted delivery of ADPR-based therapeutics, machine learning algorithms for personalized treatment and optimal dosing, wearable devices for real-time monitoring and automated dosing adjustments, computer-implemented systems for simulating treatment outcomes and predicting optimal therapeutic strategies, and mRNA-based vaccines for generating ADPR-based vaccines. These solutions work in concert to provide a comprehensive approach to ADPR-based treatments, enabling more effective prevention, diagnosis, and treatment of adenovirus-related diseases and conditions.

Novelty and Inventive Step

The inventive concept's novelty lies in its integration of advanced technologies to create a next-generation ADPR-based treatment paradigm. The inventive step resides in the specific combination and implementation of these technologies, which overcome the limitations of the original patent and provide a significant improvement in ADPR-based treatments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different nanoparticle materials, varying machine learning algorithms, or alternative wearable device designs. Variations could also include the application of the inventive concept to other disease areas or conditions, such as cancer or inflammatory disorders.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in the prevention, diagnosis, and treatment of adenovirus-related diseases and conditions. The target market includes pharmaceutical companies, biotechnology firms, and healthcare providers seeking to improve treatment outcomes and patient care.

Original Patent Information

Patent NumberUS 11,857,561
TitleMethods for the use of 5′-adenosine diphosphate ribose (ADPR)
Assignee(s)Invirsa, Inc.